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Since researchers identified a-synuclein as the principal component of Lewy bodies and Lewy neurites, studies have suggested that
it plays a causative role in the pathogenesis of dementia with Lewy bodies and other ‘synucleinopathies’. While a-synuclein dysho-
meostasis likely contributes to the neurodegeneration associated with the synucleinopathies, few direct biochemical analyses of a-
synuclein from diseased human brain tissue currently exist. In this study, we analysed sequential protein extracts from a substantial
number of patients with neuropathological diagnoses of dementia with Lewy bodies and corresponding controls, detecting a shift
of cytosolic and membrane-bound physiological a-synuclein to highly aggregated forms. We then fractionated aqueous extracts
(cytosol) from cerebral cortex using non-denaturing methods to search for soluble, disease-associated high molecular weight species
potentially associated with toxicity. We applied these fractions and corresponding insoluble fractions containing Lewy-type aggre-
gates to several reporter assays to determine their bioactivity and cytotoxicity. Ultimately, high molecular weight cytosolic fractions
enhances phospholipid membrane permeability, while insoluble, Lewy-associated fractions induced morphological changes in the
neurites of human stem cell-derived neurons. While the concentrations of soluble, high molecular weight a-synuclein were only
slightly elevated in brains of dementia with Lewy bodies patients compared to healthy, age-matched controls, these observations
suggest that a small subset of soluble a-synuclein aggregates in the brain may drive early pathogenic effects, while Lewy body-asso-
ciated a-synuclein can drive neurotoxicity.
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Abbreviations: aSyn ¼ a-synuclein; Ab ¼ beta-amyloid; CI ¼ confidence interval; DLB ¼ dementia with Lewy Bodies; ELISA ¼
enzyme-linked immunosorbent assay; HMW ¼ high molecular weight; HS ¼ high salt buffer; IHC ¼ immunohistochemistry; iPSC
¼ induced pluripotent stem cell; LB ¼ Lewy body; OG-RIPA ¼ radioimmunoprecipitation assay; PBS ¼ phosphate-buffered saline;
PD ¼ Parkinson’s disease; PI ¼ protease inhibitor; SDS ¼sodium dodecyl sulphate; SEC ¼ size-exclusion chromatography; SEM ¼
standard error of the mean.
Introduction
Dementia with Lewy bodies (DLB) is an aggressive neu-
rodegenerative disease associated with progressive cogni-
tive dysfunction and hallucinations. Neuropathologically,
the presence of intraneuronal aggregates of a-synuclein
(aSyn), similar to those of Parkinson’s disease (PD), is
diagnostic (McKeith et al., 1996; Spillantini et al., 1997;
McKeith et al., 1999; McKeith et al., 2005; McKeith
et al., 2017). In both PD and DLB, aSyn forms hallmark
perikaryal and neuritic aggregates called Lewy bodies and
Lewy neurites, in addition to more recently described
small synaptic aggregates (Kramer and Schulz-Schaeffer,
2007; Roberts et al., 2015).
aSyn is a 140-amino-acid intracellular protein with a
physiological role in regulating the trafficking of synaptic
and other small vesicles (Cabin et al., 2002; Burre´ et al.,
2010; Sharma et al., 2011; Burre´ et al., 2014; Logan
et al., 2017). To date, six different point mutations with-
in the SNCA gene have been linked to early-onset PD
and/or DLB, indicating that aSyn abnormalities can be
causative in the pathogenesis of these diseases
(Polymeropoulos et al., 1997; Kru¨ger et al., 1998;
Singleton et al., 2003; Chartier-Harlin et al., 2004;
Zarranz et al., 2004; Appel-Cresswell et al., 2013, Lesage
et al., 2013; Pasanen et al., 2014).
Despite the genetic and neuropathological evidence
suggesting a critical role for aSyn in DLB and PD
pathogenesis, the mechanism by which aSyn leads to
widespread neurodegeneration remains poorly under-
stood. The evidence in favour of the intrinsic toxicity of
Lewy bodies is conflicting (Calne and Mizuno, 2004;
Tanaka et al., 2004; Greffard et al., 2010; Osterberg
et al., 2015; Power et al., 2017). This discordance sug-
gests that the highly insoluble, presumably filamentous
aSyn in Lewy bodies may not be the principal neuro-
toxic species underlying clinical symptoms. A large body
of work, predominantly assessing recombinant aSyn,
indicates that soluble oligomers show neurotoxic proper-
ties, including a propensity to alter cellular membranes
(Volles et al., 2001; Putcha et al., 2010; Fusco et al.,
2016). Validation of these in vitro results in human tis-
sue is incomplete, however. Regional staging of aSyn
aggregates in synucleinopathy patients suggests a spatio-
temporal progression of pathology (Marui et al., 2002;
Braak et al., 2004; Deramecourt et al., 2006; Del
Tredici and Braak, 2015), potentially mediated by simi-
lar diffusible aSyn species. In fact, aSyn-containing insol-
uble extracts from human synucleinopathy brain tissue
can propagate the aggregation of endogenous aSyn in
cellular models (Prusiner et al., 2015; Woerman et al.,
2015; Cavaliere et al., 2017). In addition, previous
in vivo and in vitro studies suggest the existence of a
soluble, diffusible aSyn species that might cause the
spreading of Lewy pathology and neurotoxicity
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(Volpicelli-Daley et al., 2011; Luk et al., 2012; Kovacs
et al., 2014; Volpicelli-Daley et al., 2014; Xin et al.,
2015; Osterberg et al., 2015, Mason et al., 2016; Rey
et al., 2016; Sacino et al., 2016; Blumenstock et al.,
2017; Peng et al., 2018). Clinically, ‘post-mortem’ analy-
ses of PD patients who had received dopaminergic neu-
ron grafts showed aSyn pathology (Kordower et al.,
2008; Li et al., 2008), although this phenomenon was
not observed in all neural graft recipients (Mendez
et al., 2008), nor does it explain the selective vulnerabil-
ity of the respective neuronal populations observed in
synucleinopathies (Walsh and Selkoe, 2016).
Some work does begin to characterize these potentially
toxic aSyn species. For example, application of oligomer-
selective antibodies (Paleologou et al., 2009; Kovacs
et al., 2012) or single-chain antibody fragments (Emadi
et al., 2007; Emadi et al., 2009; Xin et al., 2015) to sol-
uble fractions of brain homogenates demonstrates the
likely presence of misfolded oligomeric aSyn species that
are distinct from the physiological multimeric aSyn that
exist in complex equilibrium with monomeric aSyn (Mor
et al., 2016; Bartels et al., 2011; Wang et al., 2011;
Burre´ et al., 2014; Wang et al., 2014; Luth et al., 2015).
Similarly, the use of a proximity ligation assay on fixed
brain tissue sections of synucleinopathy patients revealed
abundant oligomeric aSyn species previously undetectable
by traditional immunostaining methods (Kramer and
Schulz-Schaeffer, 2007; Roberts et al., 2015). Other work
has shown vesicle-associated, soluble aSyn oligomers
associated with DLB (Sharon et al., 2003).
To enrich and further characterize oligomeric aSyn
from DLB patients, we obtained tissue from
numerous post mortem brains with a neuropathological
diagnosis of DLB, histochemically confirmed the presence
aSyn Lewy-type aSyn neuronal inclusions in this tissue,
and observed substantial levels of detergent-insoluble
aSyn, as has previously been reported (Campbell et al.,
2000; Klucken et al., 2006). Fractionation of the brain
tissue extracts by ultracentrifugation and size-exclusion
chromatography (SEC) yielded buffer-soluble fractions
separated by molecular radius. We quantified buffer-sol-
uble, high molecular weight (HMW) aSyn and then
searched for specific neurotoxicity of these fractions com-
pared with simultaneously prepared cytosolic fractions of
non-neurodegenerative control brains. Given previous
in vitro studies showing the ability of aSyn to permeabil-
ize membranes (Stefanovic et al., 2015; Di Scala et al.,
2016; Ludtmann et al., 2018), we then tested the ability
of these enriched species to permeabilize lipid vesicles in
a recently developed in vitro assay (Flagmeier et al.,
2017). In addition to testing these soluble species, we
analysed detergent-insoluble material from the same
brains for neurotoxicity to elucidate the potential mode
of bioactivity of Lewy body (LB)-associated aSyn. This
study provides evidence from human samples to support
previous in vitro and animal-based work on the role of
aSyn in synucleinopathy pathogenesis.
Materials and methods
Human tissue
Human brain tissue was provided by Brigham and
Women’s Hospital (Boston, MA, USA), Mayo Clinic
(Jacksonville, FL, USA), Massachusetts General Hospital/
Massachusetts Alzheimer’s Disease Research Center
(Boston, MA, USA), Newcastle Brain Tissue Resource
(Newcastle upon Tyne, UK) and Queen Square Brain
Bank for Neurological Disorders (London, UK).
Information about the brain samples used in this study is
summarized in Table 1. Consent was obtained from
patients prior to death at each brain collection centre. All
five brain banks approved of the proposal for the use of
human tissue in this study, and the IRB at the first and
last authors’ institution deemed the planned use of this
tissue to be appropriate and ethical.
Sequential extraction of human
tissue
Frontal cortex tissue pieces weighing between 250 and
600mg were Dounce homogenized with 20 strokes at
2500 rpm using an overhead stirrer (Wheaton, Millville,
NJ, USA) in four volumes (weight:volume) tris-buffered
saline (TBS)/protease inhibitor (PI) (20mM Tris–HCl,
500mM NaCl, pH 7.5 with complete PI tablet; Sigma-
Aldrich, St. Louis, MO, USA). Homogenates were cen-
trifuged for 5min at 1000 g at 4C to remove highly
insoluble structures and debris from the tissue. The
resulting supernatants were centrifuged for 30min at
175 000 g. The high-speed supernatant was collected
as ‘cytosol’, and a small aliquot was saved for enzyme-
linked immunosorbent assay (ELISA) aSyn quantifica-
tion. The remaining supernatant was flash-frozen in
liquid nitrogen and stored at 80C until SEC fraction-
ation. The resulting pellet was resuspended in either
1% Triton X-100 (TX) in TBS or in modified radioim-
munoprecipitation assay (OG-RIPA) buffer [0.5%
Nonidet P-40 substitute, 0.5% sodium deoxycholate,
0.1% sodium dodecyl sulphate (SDS), 10mM calcium
chloride with 2% n-octyl-b-D-glucoside; Abcam,
Cambridge, MA, USA] (Kan et al., 2013) and sonicated
to homogeneity using a Dismembrator 300 Microtip
Sonicator (Fisher Scientific, Hampton, NH, USA) set to
40% output. This homogenate was centrifuged for
30min at 175 000 g at 4C. The resulting OG-RIPA
supernatants were collected, and the pellets were resus-
pended in 8M urea with 5% SDS in TBS and boiled
for 10min at 100C. The resulting TX supernatants
were collected, and the remaining pellets were resus-
pended in 5% SDS in TBS, sonicated to homogeneity
and centrifuged for 30min at 175 000 g at 4C. The
resulting SDS pellets were resuspended in 8M urea with
5% SDS in TBS and boiled for 10min at 100C.
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Comparison of membrane-
associated a-synuclein from
different extraction methods
To analyse membrane-associated aSyn levels, the 1%
Triton X-100 and 2% SDS extracts from our original ex-
traction protocol were pooled and compared with the
OG-RIPA extracts generated from our final quantitative
extraction method (Supplementary Fig. 1). Both methods
extract similar levels of aSyn by the percentage of total,
although extraction by OG-RIPA instead of TX and SDS
yielded higher levels of membrane-associated aSyn at the
expense of Lewy-associated aSyn in terms of aSyn
amount normalized to total protein.
Antibodies
2F12 and SOY1 human aSyn-specific mouse monoclonal
antibodies were used for ELISA (antibodies were developed
in-house, commercially available as catalogue no.
MABN1817 for 2F12, MABN1818 for SOY1, Sigma-
Aldrich). Site-directed mutagenesis epitope mapping
showed that 2F12 binds most strongly to a C-terminal epi-
tope corresponding to amino acids 125–135, while SOY1
Table 1 Tissue samples were collected from five separate sources: Brigham andWomen’s Hospital (Boston, MA,
USA); Mayo Clinic (Jacksonville, FL, USA); Massachusetts General Hospital/Massachusetts Alzheimer’s Disease
Research Center (Boston, MA, USA); Newcastle Brain Tissue Resource (Newcastle upon Tyne, UK); and Queen
Square Brain Bank for Neurological Disorders (London, UK)
Case # Source Diagnosis Age Sex Duration of disease (years) PMI (h)
20060025 Newcastle Probable DLB 76 M 8 13
20050022 Newcastle PD with DLB 68 F 9 69
20070105 Newcastle Probable DLB 71 M 7 8
20040085 Newcastle Probable DLB 77 M 2 29
20100353 Newcastle Cog. normal control 74 F NA 53
20100150 Newcastle Cog. normal control 77 M NA 83
A01-064 Brigham and Women’s Interstitial pneumonitis 49 F NA 25.5
A01-111 Brigham and Women’s Cog. normal control 43 F NA 23.5
A01-213 Brigham and Women’s DLB 83 M 8 54
BN14D00074 Brigham and Women’s DLB 82 M 5 <24
P80/10 Queen Square DLB 67 M 7 40
P11/11 Queen Square DLB 60 M 8 24
P20/14 Queen Square DLB 75 M 16 57
P48/07 Queen Square Cog. normal control F NA 39
1687 MGH DLB 73 M 24
1650 MGH DLB 76 M 10
1594 MGH DLB 81 F 8
1590 MGH DLB 62 M <24
1504 MGH DLB 79 F 12
1751 MGH DLB 87 F 6
1901 MGH Control 54 M NA 6
1887 MGH Control 60 M NA 14
CON 1 Mayo Clinic PA/CAA 81 F NA
CON 2 Mayo Clinic PA 75 F NA
CON 3 Mayo Clinic PA 81 F NA 22
CON 4 Mayo Clinic PA/lacune (pseudo-dementia) 75 F NA
CON 5 Mayo Clinic PA 81 M NA
CON 6 Mayo Clinic PA 78 M NA 13
CON 7 Mayo Clinic SC/VaD 79 F NA 8
CON 8 Mayo Clinic SC 70 M NA 20
CON 9 Mayo Clinic Normal (pseudo-dementia) 63 M NA 3
CON 10 Mayo Clinic PA 87 F NA 21
CON 11 Mayo Clinic PA 88 F NA 6
Syn1 Mayo Clinic DLB 81 F
Syn2 Mayo Clinic DLB 67 F
Syn3 Mayo Clinic DLB 68 F 11
Syn4 Mayo Clinic DLB 66 F 16
Syn5 Mayo Clinic DLB 79 M
Syn6 Mayo Clinic DLB 54 M 5
Syn7 Mayo Clinic DLB 62 F 7
Frontal cortex grey matter was analysed from DLB patients and corresponding controls.
CAA: cerebral amyloid angiopathy; F: female; M: male; MGH: Massachusetts General Hospital; NA: not applicable; PA: pathological aging; PMI: post-mortem interval; SC: senile
changes; VaD: vascular dementia.
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binds most strongly to a mid-region epitope corresponding
to amino acids 91–110. For comparison, sections from the
same blocks were stained with both 2F12 and LB509, a
commonly used antibody in neuropathological diagnosis of
synucleinopathies (Supplementary Fig. 2).
Immunohistochemical staining and
analysis of tissue
During frozen tissue dissection, a slice of 4-mm thick
was taken from the area adjacent to the section analysed
for aSyn content and stained as described (Sanderson,
2019). In short, the slice was submerged in 4% parafor-
maldehyde in phosphate-buffered saline (PBS) for be-
tween 72 and 96 h for fixation. Tissue was dehydrated
and embedded in paraffin. Six-micrometre sections were
cut and affixed to glass slides and dried overnight at
37C. To remove the paraffin, slides were incubated for
3min twice each in 100% ethanol, 95% ethanol and
ultrapure water. Slides were then heated for 15min by
microwave in 10mM sodium citrate and allowed to cool
to ambient temperature before a 1-h ambient temperature
incubation in 2% vol/vol fat-free milk in PBS-T. Staining
was performed using 2F12 mouse monoclonal antibody
to aSyn at a concentration of 65 ng/ml for 1 h at ambient
temperature. Following incubation in primary antibody,
slides were rinsed three times in PBS-T and then incu-
bated for 2 h at ambient temperature in biotinylated anti-
mouse IgG antibody (Southern Biotech, Birmingham, AL,
USA) prepared at 2.5 lg/ml in 2% vol/vol fat-free milk in
PBS-T. Following incubation, slides were rinsed twice in
PBS-T and once in PBS, incubated in ABC avidin–biotin
peroxidase complex (Vector Laboratories, Burlingame,
CA, USA) for 1 h at ambient temperature, and then
rinsed twice in PBS-T and once in PBS. Immunostaining
was visualized using 3,3-diaminobenzidine horseradish
peroxidase substrate (Vector Laboratories, Burlingame,
CA, USA). Slides were rinsed three times in ultrapure
water, counterstained with haematoxylin, differentiated
in 0.3% acid alcohol and dehydrated by submerging in
two baths of each of the following: 95% ethanol, 100%
ethanol and 100% xylene. Glass coverslips were mounted
in Permount (Thermo Fisher Scientific, Waltham, MA,
USA).
Denaturing a-synuclein sandwich
enzyme-linked immunosorbent
assay
All reagents were purchased from Meso Scale Discovery
(Rockville, MD, USA). Prior to ELISA aSyn quantifica-
tion, aliquots of all previously non-denatured samples
were boiled for 10min at 100C in 2% SDS. Single-spot,
standard-bind plates were coated with 200 ng of 2F12 pre-
pared in PBS and incubated overnight at 4C. Before sam-
ple loading, excess capture antibody was rinsed out and
the wells were treated with 5% MSD Blocker A in TBS-T
for 1 h at ambient temperature with shaking at 500 rpm.
Blocking buffer was removed, and the plate was rinsed
three times with TBS-T. Prior to loading, samples were
diluted in 1% Blocker A with 0.5% Nonidet P-40 substi-
tute in TBS-T to a final SDS concentration of no greater
than 0.4%. Samples were loaded in duplicate, including
amino acid sequenced recombinant aSyn standards diluted
in the appropriate detergent mixture. Plates were shaken
at 500 rpm for 1 h at ambient temperature and then incu-
bated overnight at 4C. Sample liquid was removed, the
plate was rinsed three times with TBS-T and 200 ng of
sulfo-labelled SOY1 diluted in 1% Blocker A was added
per well. The plate was light-shielded and shaken for 1 h
at ambient temperature at 500 g. The detection antibody
solution was then tapped out, and the plate was washed
three times in TBS-T. About 150 ll of 2 Read Buffer S
(diluted in ultrapure water) was added per well, and the
plate was immediately read using a SECTOR Imager
2400.
Size-exclusion chromatography
fractionation of cytosolic proteins
Between 1 and 2.5mg of total protein (measured via
Pierce BCA kit; Thermo Scientific, Waltham, MA, USA)
in 400–600 ll was injected into a 2–ml sample loop. The
sample was passed over a Superose 6 Increase 10/300GL
size-exclusion column (GE Healthcare, Pittsburgh, PA,
USA) mounted on an A¨KTA chromatography system (GE
Healthcare). The column was equilibrated with 50mM
ammonium acetate (pH 7.40). Using a flow rate of
1.5ml/min, 1ml of fractions were collected. Twenty
microlitres from each fraction was mixed with 5 ll of
10% (v/v) SDS (final SDS concentration: 2%) and boiled
for 10min at 100C for ELISA quantification. The
remaining portion of the fractions were flash-frozen in li-
quid nitrogen and either stored at 80C or lyophilized
for future analysis. For the estimation of MW, a gel fil-
tration molecular marker kit with standards ranging from
29 to 700 kDa in size (catalogue no. MWGF1000;
Sigma-Aldrich) was used to calibrate the column prior to
the analysis of brain material. These standards were used
to generate a linear model relating elution volume to mo-
lecular radius.
Permeabilization assays
The membrane permeabilization assay was performed as
previously described (Flagmeier et al., 2017). Briefly,
200mM 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine
(POPC) (16:0–18:1 PC: 18:1–12:0 Biotin PC—100:1)
vesicles were prepared by extrusion and five freeze-thaw
cycles. The lipid mixture was then hydrated in 100 mM
Cal-520 dye dissolved in HEPES buffer (50mM, pH 6.5).
Vesicles were tethered to PLL-g-PEG coated cover slides
via biotin–neutravidin linkage. The HEPES buffer was
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replaced with 50 ml Ca2þ-containing buffer solution and
blank images (Fblank) were recorded. Each field was
selected using a homemade stage-control programme to
avoid user bias. Once these fields were selected, 50 ml of
the soluble HMW fractions were added to the coverslips
and incubated for 20min before the same fields were re-
imaged (Fsample). Ionomycin was added as a positive con-
trol, and the same area containing vesicles are reimaged
(Fionomycin). The relative influx of Ca
2þ into an individual
vesicle due to aggregates of aSyn was then determined
using the following equation
Ca2þ influx ¼ Fsample  Fblank
Fionomycin  Fblank
:
For antibody experiments, the samples were incubated
with 300 nM of antibody for 20min before addition to
the coverslips. Imaging were performed using a home-
built total internal reflection fluorescence microscope
equipped with 60, 1.49NA oil immersion objective
lens. A 488-nm laser was used to excite the Cal-520 dye,
and the emitted fluorescence was collected by electron
multiplying charge-coupled device (CCD) camera.
Cell lines
All materials purchased from Thermo Fisher Scientific un-
less otherwise noted. Human embryonic kidney cells
(HEK-293; ATCC number CRL-1573) were cultured at
37C and 5% CO2 in Dulbecco’s modified Eagle’s me-
dium supplemented with 10% foetal bovine serum, 100
U/ml penicillin, 100 lg/ml streptomycin, 2mM L-glutam-
ine, 1mM sodium pyruvate and 1 minimum essential
medium (MEM) non-essential amino acids solution.
Monoclonal stable cell lines were generated by transfect-
ing with pcDNA4-A53T-huaSyn-yellow fluorescent pro-
tein using Lipofectamine 2000 according to the
manufacturer’s instructions. The transfected cells were
cultured under zeocin selection, and individual clones
were selected. N27 rat dopaminergic neural cell line was
purchased from EMD Millipore (catalogue no. SCC048,
Billerica, MA, USA) and cultured at 37C with 5% CO2
in the Roswell Park Memorial Institute (RPMI) 1640 me-
dium supplemented with 10% foetal bovine serum, 100
U/ml penicillin, 100 lg/ml streptomycin and 2mM L-glu-
tamine. Monoclonal stable cell lines were generated by
transfecting with pcDNA4-hu aSyn using Lipofectamine
2000 according to the manufacturer’s instructions. The
transfected cells were cultured under zeocin selection, and
individual clones were selected. The clone with the high-
est aSyn expression was selected for our cell viability
analysis.
Cell viability analysis
Cells were seeded at a density of 6500 cells per well on
a black poly-D-lysine (PDL) coated 96-well plate with
clear bottom (catalogue no. 354363; Corning, Corning,
NY, USA). After 24 h of culturing, cells were treated
with brain extract material for 72–96 h prior to viability
measurement. Twenty-four hours prior to measurement,
1 lM staurosporine was added to three wells as a posi-
tive control for cytotoxicity. Two hours prior to measure-
ment, culture medium was replaced with 120 ll of
culture medium with 16% (v/v) CellTiter Blue reagent
(Promega, Madison, WI, USA). Cells were cultured for
2 h, and then fluorescence was quantified using a BioTek
H1 plate reader (BioTek, Winooski, VT, USA) with an
excitation wavelength of 560 nm and an emission wave-
length of 590 nm. The average fluorescence value of three
non-cell containing wells was considered background and
subtracted from all other values during analysis.
A53T-a-synuclein-yellow fluorescent
protein inclusion formation assay
This protocol has been adapted from Woerman et al.
(2015). All reagents were purchased from Thermo Fisher
Scientific unless otherwise noted. HEK293 cells stably
expressing pcDNA4-A53T-haSyn-yellow fluorescent pro-
tein were seeded at a density of 5000 cells per well on a
black PDL-coated 96-well, clear-bottom plate (catalogue
no. 354363; Corning). Protein samples (either
recombinant monomer or pre-formed fibrils) were pre-
pared in Opti-MEM with 3% (volume:volume)
Lipofectamine 2000 and incubated at room temperature
for 2 h. Prior to cell treatment, protein-Opti-MEM-
Lipofectamine mixtures were mixed 1:1 with HEK cul-
ture medium. Culture medium on cells was removed and
replaced by 100 ll per well of these proteofection mix-
tures. Cells were cultured for 4 h with the proteofection
mixture, after which the mixture was removed and
replaced with 250 ll of culture medium. The cells were
cultured for 96 h, and fluorescent images were captured
every 2 h using the IncuCyte Zoom live cell imaging
platform (Essen Biosciences, Ann Arbor, MI, USA).
Inclusion formation assessment was performed using the
IncuCyte analysis software.
Enrichment of Lewy body-
associated brain material for
bioactivity analysis
LB-rich sequential extractions were conducted according
to the protocol published by Peng et al. (2018). Brain
pieces of 200–400mg were Dounce homogenized in four
volumes (weight:volume) of high salt buffer with PIs
(HS/PI) (50mM Tris–HCl, 750mM NaCl, 5mM ethyle-
nediaminetetraacetic acid (EDTA), pH 7.4 with complete
PI tablet; Sigma-Aldrich). Homogenates were centrifuged
at 100 000 g for 30min at 4C. Supernatants were col-
lected, and bicinchoninic acid assay for total protein
concentration was performed to assess total protein con-
centration. Pellets were then re-extracted with HS/PI
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buffer, followed by sequential extractions with 1%
Triton X-100-containing HS buffer, 1% Triton X-100-
containing HS buffer with 30% (weight:volume) sucrose
and finally 1% sodium lauroyl sarcosinate (sarkosyl)
(weight:volume)-containing HS buffer. The HSþ 1% sar-
kosyl homogenate was incubated with nutation over-
night at 4C. Following this incubation, the homogenate
was centrifuged at 100 000 g for 30min and the super-
natant was collected. The pellet was resuspended for
washing in a volume of PBS equal to the homogenate
volume initially centrifuged and then centrifuged at
100 000 g for 30min. The pellet was then resuspended
and homogenized in 0.2 volumes of the initial homogen-
ate volume of PBS using a probe sonicator. (catalogue
no. 431MPX, QSonica, Newtown, CT, USA) for 30 s
(5 s ON, 5 s OFF) at amplitude 20. After sonication,
these samples were centrifuged at 100 000 g for 20min
at 4C. The supernatant was collected and filtered
through a syringe filter (catalogue no. SLGV004SL;
Millipore Sigma) in a cell culture hood. The sterile
supernatant was then aliquoted in such that each aliquot
contained 150 ng of total protein based on the bicincho-
ninic acid protein quantification. The aliquots were
snap-frozen in liquid nitrogen in 0.5-ml Eppendorf
Protein LoBind Tubes (catalogue no. 022431081,
Eppendorf) and stored at 80C.
Harvest, culture and treatment of
hippocampal primary rat neurons
The hippocampi of E18 SD rats were dissected in Hank’s
Balanced Salt Solution buffered with HEPES and dissoci-
ated with 0.125% trypsin (Invitrogen, Carlsbad, CA,
USA) for 15min at 37C followed by trituration.
Dissociated cells were plated in 96-well plates pre-coated
with poly-D-lysine (100 lg/ml) at a density of 15 000 cells/
cm2. After culturing for 4 days in the Neurobasal medium
with B-27 supplement and Glutamax (Invitrogen), FUDR
(Sigma-Aldrich) was added to block astrocyte growth to
a final concentration of 50 lg/ml. Half of the growth me-
dium was exchanged every 4 days. Primary rat hippocam-
pal neurons were cultured for 14 days in vitro (DIV14)
as described previously (Jin et al., 2011). At DIV14,
pooled and lyophilized HMW SEC fractions (2–8) were
resuspended in culture medium and applied to the cells in
triplicate. Neurite length was monitored over 72 h using
the IncuCyte live cell imaging platform (Essen
Biosciences).
Culture and treatment of human
induced pluripotent stem
cell-derived neurons
The induced pluripotent stem cell (iPSC) line used in this
study (YZ1) was originally generated from the IMR-90
cell line (ATCC) and characterized as described
previously (Zeng et al., 2010). Due to a karyotype abnor-
mality in a small subset of cells, monoclonal isolates
were obtained and confirmed to be karyotypically normal
and pathogen-free prior to this study (Srikanth et al.,
2018). The iPSC line used was confirmed to be of the
correct identity using short tandem repeat profiling
(Genetica Cell Line Testing). iPSCs were maintained in
media containing 400ml of Dulbecco’s modified Eagle’s
medium/F12 (Invitrogen), 100ml of KnockOut Serum
Replacement, 5ml of penicillin/streptomycin/glutamine,
5ml of MEM non-essential amino acids and 500ll of 2-
mercaptoethanol (all from Invitrogen) with fresh addition
of 10 lg/ml fibroblast growth factor-basic (bFGF)
(Millipore). The differentiation was achieved through neu-
rogenin expression under a doxycycline promotor as pre-
viously reported with minor modifications (Zhang et al.,
2013). Induced neurons, which are described as a homo-
genous population of neurons expressing VGLUT2, a
transporter for the excitatory neurotransmitter glutamate,
were plated at DIV4 on 96-well plates (Greiner Bio-One,
Monroe, NC, USA) pre-coated with Matrigel (Corning)
at a density of 5000 cells per well and maintained in
media consisting of 1% Glutamax (volume:volume),
0.3% dextrose (weight:volume) and 0.5% MEM non-es-
sential amino acids (volume:volume) in the Neurobasal
medium. Two percent B27 supplement (v/v), brain-
derived neurotrophic factor (BDNF), ciliary neurotrophic
factor (CNTF), glial cell line-derived neurotrophic factor
(GDNF) (10 ng/ml each), puromycin (1 lg/ml) and doxy-
cycline (2 lg/ml) were added just prior to feeding.
Differentiated cells were treated between DIV21 and
DIV28 with insoluble extracts prepared as described
above containing 50 ng of total protein per well and
brought to a final volume of 200 ll. Cells were treated in
triplicate wells with randomized locations. During the
course of the treatment, the cells underwent a single me-
dium replacement of 50% of the volume in each well.
Neurite morphology analysis
The IncuCyte automated live cell imaging platform cap-
tured phase contrast images every 2 h over a total of 88–
96 h. Neurite and cell body masks were applied to the
images (Supplementary Fig. 3). Average neurite length
and cell body cluster area were measured using the
IncuCyte image capture and analysis software in
Neurotrack mode. To compare neurite degeneration be-
tween wells, average neurite lengths at 88 h were divided
by the normalized average neurite lengths in the same
field at 0 h. This was compared to the same ratio in un-
treated wells.
Statistical analysis
Prism (GraphPad, San Diego, CA, USA) was used for all
statistical analyses and graph generation. Details of each
analysis are provided in the relevant figure legends.
Analysis of a-synuclein from human tissue BRAIN COMMUNICATIONS 2020: Page 7 of 17 | 7
Means6 standard error of the means (SEMs) are shown
in cohort-wide analyses, while means6 standard devia-
tions are shown in single-patient analyses.
Data availability
The data that support the findings of this study are avail-
able from the corresponding author upon request.
Results
a-Synuclein is differentially
distributed in subcellular
compartments in dementia with
Lewy Bodies cortical tissue
Using sequential extraction with solvents of increasing
denaturing capability, we quantitatively analysed the rela-
tive solubility of aSyn in frontal cortical extracts from 22
DLB patients and 18 non-synucleinopathy control subjects
(Table 1). Analysis of demographic data showed no differ-
ence in ages or post-mortem intervals between the two
populations (P¼ 0.929 and P¼ 0.980, respectively, un-
paired T-tests). No post-mortem interval data were pro-
vided for 6 of the 22 DLB brains and 4 of the 18 control
brains, and no ages were given for one of the 18 control
brains. In addition, chi-square analysis showed no signifi-
cant deviation from the expected gender ratios (P¼ 0.262)
(Table 2). To minimize the significant variation we
observed in both the levels of ‘insoluble’ aSyn (insoluble
in OG-RIPA but soluble in 5% SDS/8M urea-soluble) and
the degree of Lewy cytopathology by aSyn immunohisto-
chemistry (IHC) (Fig. 1), we homogenized between three
and six different tissue pieces dissected from frozen frontal
cortex of each DLB brain that showed Lewy pathology by
aSyn IHC in sections prepared from a piece of the adja-
cent frozen cortex. When thawed, each of these pieces
weighed 50mg. Small aliquots of each extraction frac-
tion were denatured by boiling in 2% SDS to measure
total aSyn amount by sandwich ELISA. To account for
possible shifts in cell populations in diseased tissue, such
as the presumed loss of aSyn-expressing neurons and the
local invasion of non-expressing glia, we expressed the
data in aSyn levels as a percentage of the total aSyn
recovered from all three fractions (Fig. 2). We also
expressed the absolute amount of aSyn in each sequential
extract normalized to total protein (per a bicinchoninic
acid total protein assay) in Supplementary Fig. 4.
While this extraction was designed primarily to identify
small brain pieces with high pathology burden based on
the established finding that detergent-insoluble aSyn is
associated with high histopathological LB density
(Campbell et al., 2000; Klucken et al., 2006), we also
included a membrane-associated fraction to examine the
subcellular localization of aSyn in our relatively large,
multi-centre collection of human samples. Expressing the
three extract fractions (cytosol, membrane extract and
urea-solubilized extract) as a percentage of total recov-
ered aSyn showed differences in the solubility distribu-
tions of aSyn extracts from control compared with
synucleinopathy tissue. DLB cytosols contained a higher
proportion of extracted aSyn than those of controls,
whereas membrane-associated fractions showed the op-
posite: DLB samples had a lower proportion of total
extracted aSyn (Fig. 2A). This observation suggests a par-
tial redistribution of membrane-bound aSyn to the cyto-
solic compartment in the affected DLB cortex. Although
correlation analyses of related percentages, by definition,
show strong associations, we interrogated whether the
relative strengths of these associations on a sample-to-
sample basis suggested a predictable redistribution of
aSyn from one compartment to another. Stratification of
DLB brain extracts into low aSyn burden (insoluble
aSyn< 1%) and high aSyn burden (insoluble aSyn> 1%),
and analysis of membrane:cytosol aSyn ratio showed a
relative shift to the cytosolic compartment in high-insol-
uble aSyn brains, suggesting that insoluble aSyn may
come from the membrane compartment (Fig. 2B). This
result supports recent research showing an abundance of
vesicle-bound aSyn in Lewy bodies (Shahmoradian et al.,
2019) and reinforces the hypothesis that vesicle binding
increases aSyn aggregation (Galvagnion et al., 2015). As
expected, in control subject brain samples, there was
nearly perfect linear correlation between the cytosolic and
membrane-associated aSyn, as physiological aSyn likely
exists in a rapid equilibrium between its soluble and
membrane-bound forms [Spearman r¼1.000, 95% con-
fidence interval (CI): 1.000 to 1.000, P< 0.0001]
(Fig. 2C). Because the aSyn extracted from DLB patient
brains was spread across all three fractions, with variable
elevations in the final urea-solubilized extract (Fig. 2A,
right), this correlation was not as strong in DLB
(Spearman r¼0.609, 95% CI: 0.721 to 0.462,
P< 0.0001) (Fig. 2C). Looking exclusively at DLB patient
brains, there were strong negative associations between
the insoluble fractions and the cytosolic and membrane
fractions (insoluble versus cytosol: Spearman r¼0.298,
95% CI: 0.469 to 0.105, P¼ 0.0023; insoluble versus
membrane: Spearman r¼0.315, 95% CI: 0.484 to
0.124, P¼ 0.0012) (Fig. 2D and E). In analysis of the
brains obtained from the Mayo Clinic brain bank, which
Table 2 Unpaired T-tests showed no significant differ-
ence between the mean ages or PMIs of the control
and DLB patient samples
Control (N518) DLB (N5 22) P-value
Age 72.86 13.5 72.56 8.6 0.93
PMI 24.16 20.9 23.96 20.5 0.98
Gender (F:M) 11:7 9:13 0.26
A chi-square test also showed no significant difference in the F:M reported gender
ratios between the groups.
F: female; M: male; PMI: post-mortem interval.
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had exceptionally high levels of insoluble aSyn (Fig. 2F),
both of these negative correlations were even stronger.
This suggests that in patients with a high burden of LB
pathology, aSyn from both the cytosolic and membrane-
associated physiological pools contributes to the forma-
tion of the insoluble aggregates (insoluble versus cytosol:
Spearman r¼0.900, 95% CI: 0.954 to 0.89,
P< 0.0001; insoluble versus membrane: Spearman
r¼0.415, 95% CI: 0.689 to 0.386, P¼ 0.0028)
(Fig. 2G and H).
Looking at the absolute aSyn concentrations in each
fraction, we observed significantly lower levels of mem-
brane-associated aSyn in DLB than control cortex
when normalized to total protein (P< 0.0001)
(Supplementary Fig. 4A) and robust regression and out-
lier removal outlier removal did not alter this finding.
aSyn content in the urea-soluble extracts confirmed
that DLB cortex had greater levels of highly insoluble
aSyn than did control cortex (P< 0.0001)
(Supplementary Fig. 4A). As expected, only negligible
amounts of aSyn were detected in the urea-solubilized
fraction of control brains, indicating that the aSyn
detected in this fraction derives from the hallmark
aggregated aSyn lesions of DLB.
Analyses of the of log-normalized absolute aSyn levels
(Supplementary Fig. 4B–D) in the three different extracts
revealed associations of aSyn levels between fractions.
Cytosolic absolute aSyn levels from frontal cortex (whether
DLB or control) correlated strongly with membrane-associated
absolute aSyn levels (control: Spearman r¼ 0.656,
P< 0.0001, 95% CI: 0.494–0.770, DLB: Spearman r¼ 0.761,
P< 0.0001, 95% CI: 0.662–0.834) (Supplementary Fig. 3B).
Detergent-insoluble/urea-solubilized (Lewy-associated) aSyn
levels showed no significant relationships with membrane or
cytosolic aSyn levels in DLB extracts (insoluble versus cytosol:
Spearman r¼0.078, 95% CI: 0.118 to 0.267,
P¼ 0.436; insoluble versus membrane: Spearman r¼0.026,
95% CI: 0.174 to 0.224, P¼ 0.793) (Supplementary Fig.
4C and D), except for a subset of DLB samples with the most
severe LB/Lewy neurite pathology burden by high levels of in-
soluble aSyn in the corresponding urea extracts. Specifically,
DLB frontal cortices from the Mayo Clinic brain bank that
had very high levels of insoluble, Lewy-associated aSyn
(Supplementary Fig. 4E–G), showed strong negative correla-
tions between those levels and both cytosolic and membrane-
associated aSyn (insoluble versus cytosol: Spearman
r¼0.719, 95% CI: 0.864 to 0.464, P< 0.0001; insol-
uble versus membrane: Spearman r¼0.563, 95% CI:
0.778 to0.230, P¼ 0.0018).
Analysis of this protein-normalized aSyn content in
each fraction revealed a significant decrease in the
mean level of total extracted aSyn in DLB frontal
homogenates versus controls by 25% (P¼ 0.0016,
Mann–Whitney comparison of ranks) (Supplementary
Fig. 4A). Analysis of cytosolic fractions yielded a simi-
lar result: on average, there was significantly less aSyn
in DLB extracts than in control (P¼ 0.010)
(Supplementary Fig. 4A).
Notably, analysis comparing the subcellular local-
ization of aSyn in extracts of two brains of patients
with familial DLB (one A53T aSyn mutant and one
SNCA duplication carrier) did not show striking
Figure 1 IHC confirmation of synucleinopathy in DLB frontal cortical samples. (A) IHC of the formalin-fixed striatum of MGH DLB
brain #1594 with aSyn monoclonal antibody 2F12 demonstrates the striking local heterogeneity of cytopathology. Yellow box: area of high
density of Lewy cytopathology; blue box: immediately adjacent area devoid of IHC-detectable aSyn aggregates. Scale bars: 300 lm. (B) Small
frozen pieces of tissue were excised from locations adjacent (within 5 mm) to the frozen pieces we used for our biochemical extractions. The
resultant cryostat sections were stained with aSyn monoclonal antibody 2F12 and nuclei counterstained with haematoxylin. Representative
images from two control and two DLB brains show ice crystals resulting from variable freezing of the unfixed tissue. Arrows exemplify LBs;
arrowheads exemplify Lewy neurites. Scale bars: 80 lm.
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Figure 2 aSyn solubility distribution in DLB versus control brains based on the percentage of total analysis. (A) For each tissue
piece (represented by a single point), the ELISA-measured aSyn concentration was multiplied by the original volume of the extract, yielding the
total aSyn in each fraction. This was then expressed as a percentage of the total aSyn recovered in all three fractions. Graphs: percentage of
total aSyn in the cytosolic, membrane (1% Triton-soluble) and insoluble (SDS/8 M urea-soluble) extracts. Between three and eight tissue pieces
were processed and analysed per brain, and each piece was measured in triplicate. Bars: means with SEMs. Control and DLB extracts were
compared using the Mann–Whitney comparison of ranks. (B) DLB brain extracts were stratified based on insoluble aSyn quantities (blue: <1%
of total extracted aSyn; purple: >1% of total extracted aSyn), and the ratio of membranous to cytosolic aSyn was calculated for each group.
Proportionally, this analysis revealed higher membranous aSyn in low-pathology DLB extracts (P< 0.0001, Mann–Whitney comparison of ranks).
(C) Correlation analyses of the percentages of recovered aSyn in the cytosolic and membrane cortical fractions, both from control subject and
DLB patient brains, showed strong negative associations, an unsurprising finding given that these fractions contain most of the total extracted
aSyn (control: Spearman r¼1.000, 95% CI: 1.000 to 1.000, 2-tailed P< 0.0001; DLB: Spearman r¼0.609, 95% CI: 0.721 to 0.462,
P< 0.0001). (D and E) Strong negative associations also exist between the percentage of total extracted aSyn in the insoluble fraction and the
percentage of total extracted aSyn in both the cytosolic and membrane-associated fractions across all cortical extracts from DLB patient brains
(insoluble versus cytosol: Spearman r¼0.298, 95% CI: 0.469 to 0.105, P¼ 0.0023; insoluble versus membrane: Spearman r¼0.315, 95%
CI: 0.484 to 0.124, P¼ 0.0012). (F) In terms of insoluble aSyn as a percentage of total extracted aSyn, DLB patient brains from the Mayo
Clinic brain bank showed the highest pathological burden. Means with standard deviations are shown. (G and H) Correlation analyses comparing
the percentage of total extracted aSyn in insoluble fractions to cytosolic and membrane-associated fractions from these high-burden Mayo Clinic
brains showed even stronger negative associations than the analyses that included DLB patient brains from all sources (insoluble versus cytosol:
Spearman r¼0.900, 95% CI: 0.954 to 0.89, P< 0.0001; insoluble versus membrane: Spearman r¼0.415, 95% CI: 0.689 to 0.386,
P¼ 0.0028).
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differences compared with the pooled data from all
control extracts (Supplementary Fig. 5A). Statistical
analyses were not performed due to the disparate
sample sizes.
Soluble, high molecular weight
a-synuclein species are more
abundant in dementia with Lewy
Bodies than control cortical
extracts
The cytosolic fractions of brain pieces with high levels of
aSyn in the urea extracts were fractionated using non-
denaturing SEC on a column with a 3-MDa exclusion
size to probe for relative abundance of a range of HMW
forms of soluble aSyn. After SEC fractionation, small ali-
quots of each fraction were boiled in 2% SDS for 10min
to denature the samples and maximally expose epitopes
prior to aSyn ELISA quantification. Across all samples,
an average of 91.2% of soluble aSyn eluted in SEC frac-
tions 11–13, which correspond to the expected elution
volume of physiological aSyn (MW of 80 kDa based on
the elution of recombinant protein standards;
Supplementary Fig. 6). Comparison of aSyn levels in indi-
vidual SEC fractions of control and DLB cytosols
revealed no statistically significant differences (Fig. 3A).
However, pooling the individual levels across the HMW
SEC fractions (i.e. fractions 2–8, corresponding to 2
MDa down to 440kDa, Supplementary Fig. 6) revealed
a significant increase in relative levels of soluble, HMW
aSyn in cytosols of DLB versus control cortex
(P¼ 0.0256, Mann–Whitney comparison of ranks)
(Fig. 3B). On average, the aSyn content of these HMW
SEC fractions comprised only 1.0% (in control cortex)
and 1.4% (in DLB cortex) of the total eluted cytosolic
aSyn, indicating that in the diseased brain, HMW-soluble
aSyn species is relatively elevated but still not abundant,
similar to previous observations of tau protein species
present in Alzheimer’s disease brain (Takeda et al.,
2015).
Soluble a-synuclein species increase
the permeability of lipid
membranes in vitro
We then tested whether the soluble, HMW SEC frac-
tions of brain cytosols were capable of phospholipid
membrane permeabilization. We used a previously
described membrane permeabilization assay that utilizes
nanosized lipid vesicles tethered to a coated glass surface
via biotin–neutravidin linkage and filled with a Ca2þ-
sensitive dye (Flagmeier et al., 2017). Influx of Ca2þ
into these vesicles from the surrounding buffer was
measured using total internal reflection fluorescence mi-
croscopy (Fig. 4A). We applied the pooled HMW SEC
fractions (fractions 2–8, corresponding to a molecular
weight of 2MDa–440 kDa) from cytosolic extracts of six
DLB and six control brains to this assay. Extracts from
both subject groups caused influx of Ca2þ, indicating
the destabilization of lipid membranes (Fig. 4B). On
average, application of pooled HMW fractions cytosolic
extracts from DLB brains destabilized membranes signifi-
cantly more than corresponding extracts from control
subject brains (Mann–Whitney comparison of ranks,
P¼ 0.0087; Fig. 4C). Interestingly, samples from brains
Syn3 and Syn6 caused complete permeabilization of lipid
vesicles. Importantly, immunoneutralization of these
samples with an aSyn-specific monoclonal antibody
(2F12), but not a beta-amyloid (Ab)-specific monoclonal
antibody (4G8), markedly decreased the Ca2þ influx
(paired T-test, two-tailed P¼ 0.0045). This indicates that
the active species in these DLB cortical fractions that po-
tently enhance membrane permeabilization are composed
of aSyn (Fig. 4D). This finding provides validating
human support of similar results obtained in both
in vitro and mouse models with aSyn fibrils (Fusco
et al., 2016; Mor et al., 2017). Interestingly, despite un-
remarkable shifts in subcellular localization of aSyn
compared with control extracts (Supplementary Fig. 5A),
the two familial DLB brain extracts significantly
increased the permeabilization of these vesicles
(Supplementary Fig. 5B, Mann–Whitney comparison of
ranks, P< 0.0001 for both brains). This increase in per-
meabilization appeared dependent on the presence of
exposed aSyn epitopes (Supplementary Fig. 5C),
Figure 3 Size distribution of soluble aSyn from DLB and
control frontal cortex. TBS-soluble, post-175 000 g
supernatants from cortical pieces with high levels of insoluble
(Lewy-associated) aSyn and corresponding controls were
fractionated by SEC (3 MDa exclusion size; see Materials and
methods). To correct for the amount of aSyn injected into the SEC
column for each case, aSyn levels for each fraction were expressed
as a percentage of total aSyn recovered across all the SEC fractions.
(A) Percentage of total aSyn in each SEC fraction (means with SEMs
are shown); elution of marker proteins indicated in kDa. Inset: aSyn
recovered in HMW fractions 2–8, corresponding to MWs from
2 MDa to 440 kDa. (B) Pooling the HMW fractions revealed
significantly higher mean aSyn levels in DLB cytosolic extracts than
controls (P¼ 0.0256, Mann–Whitney comparison of ranks). DLB:
n¼ 1–4 cytosolic fractions per subject; controls: n¼ 1–8.
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although this dependence did not meet the level of statis-
tical significance (paired T-test, P¼ 0.206).
Insoluble a-synuclein from dementia
with Lewy Bodies brain extracts
induces morphological changes in
human induced pluripotent stem
cell neurons
To assess the potential neurotoxicity of insoluble,
Lewy-associated aSyn, we generated a sonically
dispersed preparation of detergent-insoluble cortical
protein using density gradient centrifugation and par-
tial detergent treatment (Blumenstock et al., 2017).
These sonicated brain extracts were added to a homo-
genous population of iPSC-derived, neurogenin-2-
induced human excitatory neurons (Zhang et al.,
2013), and neurite morphology was monitored over
88 h (Fig. 5A and Supplementary Fig. 3). Previous
works have shown that alterations in the morphology
of neurite processes are sensitive indicators of neuro-
toxicity (Stephens et al., 2005; Scott et al., 2010;
Domı´nguez-A´lvaro et al., 2018). Significantly, the par-
ticular commercial live-imaging platform used to assess
morphological changes in neurons relies not on the ex-
pression of non-physiological, but rather on the light
microscopy coupled with a computer algorithm for
detecting and applying masks to either neurites or cell
bodies. For this assay, we applied extracts from five
DLB brains with the highest levels of detergent-insol-
uble/8M urea-solubilized aSyn and four corresponding
control brains. The effects of these extracts on neurite
length showed significant variability across both con-
trol and DLB brain samples (Fig. 5B), but when data
were aggregated based on neuropathological diagnosis,
the DLB extracts led to significantly lower mean neu-
rite length than did the control extracts (P¼ 0.0066,
Mann–Whitney comparison of ranks) (Fig. 5C).
Comparison of cells treated with Ab-immunoneutral-
ized extracts (4G8 antibody) with those treated with
aSyn-immunoneutralized extracts (2F12 antibody) did
not show a significant difference. However, there was
a trend towards shorter neurite length in the Ab-immu-
noneutralized extracts (P¼ 0.0703, Wilcoxon paired
comparison of ranks), suggesting that the toxicity of
these extracts is driven primarily by pathological aSyn,
not Ab (Fig. 5D).
Discussion
Using non-denaturing biochemical fractionation of human
frontal cortex to avoid potential denaturation of endogen-
ous aSyn species (Luth et al., 2015), we have character-
ized the oligomeric landscape of a variety of DLB and
control brain tissue samples and validated the existence
of neurotoxic soluble aSyn species in human brain. We
report and describe a number of biochemical findings,
tightly correlating with neuropathology, which could help
elucidate the role of aSyn in the inception and progres-
sion of synucleinopathies. In addition, we identified pieces
of tissue from our collection with both biochemical and
neuropathological evidence of significant aSyn disease
burden, establishing a method to identify pathology-rich
tissue pieces for further analysis of corresponding soluble
species. Notably, we observed a high degree of ‘microhe-
terogeneity’ within single sections of tissue, both by IHC
(Fig. 1) and biochemistry (Fig. 2). This observation drove
Figure 4 Quantitative measurement of membrane
permeabilization upon applying HMW fractions of soluble
brain extracts via fluorescence imaging. (A) Images obtained
through TIRF microscopy show an untreated vesicle sample (top,
‘Control’), a vesicle sample treated with soluble, HMW brain
material from DLB patient 1594 (middle) and a sample treated with
ionomycin as a positive control (bottom). Scale bars are 3 lm.
(B) Brain homogenates display variable vesicle permeabilization
capability between different cases but low variability within
replicates of the same samples. Means with standard deviations are
shown. (C) Mann–Whitney comparison of ranks analysing average
Ca2þ influx measured from six DLB and six control brains reveals
significantly elevated permeabilization of lipid membranes by soluble
extracts from DLB patients (P¼ 0.0087). For each patient sample,
nine technical replicates were used to generate the data point.
Means with SEMs are shown. (D) Immunoneutralization of DLB
cytosolic extracts with 2F12 anti-aSyn antibody (2F12, right)
reduces the DLB extract-induced permeabilization of the vesicles
compared to immunoneutralization anti-Ab antibody (4G8, left)
(paired T-test, P¼ 0.0045). For each patient sample, nine technical
replicates were used to generate the data point. Each pair of points
connected by a line represents a single cytosolic HMW extract. The
two pairs of points denoted by a ‘*’ came from a single DLB brain
(Syn2).
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Figure 5 Treating iPSC-derived human neurons with Lewy-associated brain extracts. (A) Neurogenin-induced human neurons were
treated with protein-normalized volumes of sonicated Lewy-associated brain extracts. Neurite morphology was monitored for 88–96 h. Images
were analysed by applying a neurite mask (Supplementary Fig. 5) and automatically quantifying mean neurite length. In these representative
images, neurons treated with aSyn-enriched control brain extract (top) show largely intact neurites at 52 h, whereas neurons treated with A01-
213 DLB aSyn-enriched extract display neurite retraction (bottom). Images shown from each brain sample are taken from identical fields at
different time points. Bars are 200 lm. (B) Mean neurite length calculated across four images per well at 88 h was normalized to the mean
neurite length at t¼ 0. While the amount of aSyn levels applied to each well was not normalized, these levels did not correlate with the extent of
neurite retraction (not shown). Means with standard deviations are shown. (C) Pooling of data collected from four non-synucleinopathy control
extracts and five DLB patient extracts across three separate experiments shows a significantly greater neurite retraction in neurons treated with
DLB extracts (P¼ 0.0066, Mann–Whitney comparison of ranks). Means with SEMs are shown. (D) Human iPSCs were treated with two extracts
from five DLB brains, each split into three aliquots: one was applied directly; one was pre-incubated with 2F12, a monoclonal antibody to aSyn;
and a third was pre-incubated with 4G8, a monoclonal antibody to Ab. Immunoneutralization of aSyn in these extracts restored the length of
neurons treated compared with neurons treated with non-immunoneutralized aliquots of the same DLB extracts (P¼ 0.0078, Wilcoxon paired
comparison of ranks). Each point represents the mean of technical triplicates from a single experiment. Means with SEMs are shown.
Analysis of a-synuclein from human tissue BRAIN COMMUNICATIONS 2020: Page 13 of 17 | 13
our decision to look at several small tissue pieces per
brain, as we feared that unburdened areas of larger sec-
tions of tissue might dilute any pathology-specific effects
and we recommend future studies to employ a similar
approach.
Through the quantification of aSyn levels in fractions
generated through our extraction process, we observed
differences in the subcellular distribution of aSyn species
in DLB brains compared with controls. Analysis of our
most pathology-rich tissue indicated that the aSyn levels
in the cytosolic and membrane fractions of a single tissue
piece were associated with the degree of Lewy neuropath-
ology as determined by its level of insoluble aSyn. The
strong inverse relationship between the relative levels of
pathological, Lewy-associated aSyn and cytosolic or
membrane-associated aSyn implies that the accumulation
of insoluble aSyn is accompanied by a relative decrease
in its physiological pools. Our observation that strong
aSyn pathology is directly associated with a decrease in
physiological aSyn in the same small samples of DLB
cortex supports the possibility of a loss-of-function of
physiological aSyn in the disease (Gorbatyuk et al.,
2010a, b; Benskey et al., 2016).
Our analysis of the absolute concentrations of aSyn in
different fractions points towards this possibility: in
patients with DLB, there were lower total levels of aSyn,
an expected consequence of late-stage disease with
accompanying neuronal loss. At the same time, according
to our analyses, the remaining aSyn redistributes to the
cytosolic and urea-solubilized fractions. We found the
relative biochemical increase in urea-solubilized aSyn to
be associated with the presence of insoluble aSyn aggre-
gates, which are the histopathological hallmarks of DLB
and the other synucleinopathies. However, the relative in-
crease in cytosolic aSyn in DLB cortex is not as readily
explained. Our native SEC-ELISA analyses do show a sig-
nificant increase in soluble, HMW species that could con-
tribute to this redistribution; however, these species are
of very low abundance, comprising 0.1–1% of the total
extractable aSyn in our assays. Alternatively, the shift in
relative abundance away from the membrane-associated
fraction to the cytosolic fraction may be related to a loss
of physiological function. Previous work has shown that
transient interactions with phospholipid membranes in-
duce proper folding and assembly of aggregation-resistant
multimeric aSyn (Rovere et al., 2018), and it appears
that aSyn is likely involved in the physiological recycling
of exocytotic (including synaptic) vesicles (Logan et al.,
2017). In addition, recent studies have shown that alter-
ing the lipid composition of vesicles can mitigate aSyn-
related toxicity (Fanning et al., 2019; Vincent et al.,
2018). Thus, it is possible that in the pathological state,
more aSyn is in a disordered, cytosolic state that is more
prone to aggregation than the multimeric state (Bartels
et al., 2011).
In further analysis of the cytosolic fractions, SEC-
ELISA fractionation and analysis showed that, propor-
tionally, HMW aSyn species are more abundant than in
simultaneously and identically prepared extracts of age-
matched control cortex. These soluble HMW species
span a broad distribution of apparent sizes (440 kDa–
3MDa). Despite this finding, the low absolute levels of
soluble HMW aSyn in both DLB and control cortex
posed a challenge for further analyses and characteriza-
tions. In fact, the total amount of aSyn in these fractions,
even when pooled, was close to the lower limit of quanti-
fication of our ELISA (0.5–1 ng/ml) than to the minimum
concentration of synthetic aSyn pre-formed fibrils
required to see an effect in our assays (500 ng/ml). While
we observed no frank neurotoxicity of these fractions in
a neurite outgrowth assay, our vesicle permeabilization
assay indicated that these fractions can decrease phospho-
lipid membrane integrity in an aSyn-dependent manner,
an effect that likely contributes to neurotoxicity over
time. The disparate sensitivities of our assays and the low
concentrations of aSyn in these soluble extracts might ex-
plain the apparent lack of neurotoxicity. However, our
findings in a vesicle permeabilization assay indicate that
low amounts of HMW aSyn present in DLB brain cortex
are qualitatively different than HMW aSyn present in the
control cortex of aged brains and suggest a possible
mechanism of toxicity.
We also examined the toxicity of the Lewy-associated
aSyn species that are enriched in our detergent-insol-
uble, urea-solubilized fraction. These insoluble species
alone demonstrated the ability to alter neurite morph-
ology in human iPSC-derived neuronal cultures
(Fig. 5), providing evidence that highly aggregated
aSyn species found in LBs and Lewy neurites may con-
tribute to the cytotoxicity that leads to the neurodegen-
eration and clinical manifestation of synucleinopathies.
Given that the levels of cytosolic aSyn (including the
soluble HMW aSyn species) correlate inversely with the
levels of insoluble aSyn in our collection of DLB front-
al cortices (Fig. 2F), we speculate that the soluble
aggregates are an intermediate species that both direct-
ly contribute to neurotoxicity and deplete pools of
physiological aSyn, analogous to the proposed role of
amyloid plaques in Alzheimer’s disease (Martins et al.,
2008; Shankar et al., 2008).
In conclusion, this study characterizes aSyn-specific
biochemical differences in a large sample of DLB and
control brain tissue for the first time. We also report
on challenges associated with working with multiple
brain banks. We hope that reporting on these chal-
lenges may standardize future tissue collection and clas-
sification protocols. In addition, bioassays of aSyn-
enriched DLB samples provide more clues that should
guide future research into the toxic mechanism of
pathological aSyn.
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